GN25
目录号 : GC15258
Inhibits p53-Snail binding
Cas No.:1227401-27-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GN25 is a novel inhibitor of Snail-p53 binding [1].
P53 is a tumor suppressor that induces cell death, growth arrest and suppresses metastasis, and is often mutated or suppressed by various kinds of cellular signaling pathways in human cancers. In K-Ras-activated cancer cells, oncogenic K-Ras inhibits the p53 function through induction of Snail, which binds to and eliminates p53 through exocytosis. The specific inhibitor against p53-Snail binding would be used as anticancer drug against K-Ras-mutated or Snail-overexpressed cancers such as colon, pancreatic and lung cancers [1].
GN25 is a novel and specific inhibitor of Snail-p53 binding. GN25 is a 2-thio-dimethoxy naphthoquinone analog that induces p53 and p21 expression, and blocks the p53-Snail binding. In K-Ras-transformed mouse embryonic fibroblast (MEF), GN25 induced p53 and p21 in K-Ras-dependent way. In assay with capan-1 extract, GN25 significantly reduced interaction between p53 and Snail [1].
In nude mice inoculated A549 cells through i.p. injection, GN25 blocked the tumor progression and also induced tumor regression [1].
Reference:
[1]. Lee SH, Shen GN, Jung YS, et al. Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells. Oncogene. 2010 Aug 12;29(32):4576-87.
| Cas No. | 1227401-27-5 | SDF | |
| 化学名 | 3-[(1,4-dihydro-5,8-dimethoxy-1,4-dioxo-2-naphthalenyl)thio]-propanoic acid | ||
| Canonical SMILES | O=C1C=C(SCCC(O)=O)C(C2=C(OC)C=CC(OC)=C21)=O | ||
| 分子式 | C15H14O6S | 分子量 | 322.3 |
| 溶解度 | ≤0.25mg/ml in ethanol;5mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1027 mL | 15.5135 mL | 31.027 mL |
| 5 mM | 0.6205 mL | 3.1027 mL | 6.2054 mL |
| 10 mM | 0.3103 mL | 1.5513 mL | 3.1027 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet